An NGT bench, comprising chairperson justice Prakash Shrivastava and expert member Dr A Senthil Vel, observed “adequate action has already been taken against illegal felling which has taken place”.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...